Ideas catalog
Every idea we've derived from recent research — the ones marked “Prototype” come with a live demo you can try.
A focused proxy-marker assay for tire pollution monitoring that is technically feasible but rests entirely on a single paper's correlation that may not generalize across tire formulations and regions.
A genuinely novel oral probiotic concept with a sharp wedge into the nitrate-supplement stack, but resting on a single review paper with no clinical proof that lozenge-delivered strains colonize, persist, and meaningfully elevate systemic nitrite in humans.
A timely Euro 7-driven non-exhaust PM testing service with a credible technical basis, but capital-intensive and competing against the very named incumbents that already own dyno infrastructure.
A regulation-driven brake module with a single quantified emission-reduction claim, but built on one study and competing against incumbent suppliers' own Euro 7 solutions.
A technically sound, well-targeted bean-breeding program that smartly exploits a clean monogenic resistance trait, but it relies on a single study, uses standard (non-novel) breeding techniques, and faces a low-margin, donor-dependent smallholder seed market.
A low-moat consultancy play that repackages existing public IPCC data into reports, lacking a scalable product edge or proprietary technology.
A generic application of educational psychology textbooks that lacks a proprietary technical edge and faces significant adoption hurdles in the K-12 market.
A credible niche tooling idea for EV eco-driving HMI validation, but built on a single research group's framework with an unproven licensing market and incumbents who could replicate it.
Backed by 2 papers
A focused, technically credible assay concept with a clean wedge over pyrolysis-GC/MS, but its commercial foundation rests on a single study calling these 'candidate markers' — cross-geography and cross-matrix validation is still the critical missing proof point.
A well-grounded but derivative idea — refrigerant destruction credits already exist (Tradewater, VCS/ACR protocols) and the paper's MFA baseline, while rigorous, does not by itself constitute a defensible commercial wedge against incumbents.
A timely and focused clinical tool addressing a genuine force-prediction gap in direct-print aligner adoption, but the translation from flat-specimen in vitro curves to validated in-mouth force delivery is a large, underacknowledged step that weakens both the evidence base and near-term feasibility.
Backed by 2 papers
A generic mental health app for a niche problem that lacks a clear B2B incentive and faces high competition from existing wellness tools.
A necessary but generic hardware play that lacks a specific technical breakthrough, relying on a broad review paper rather than a proprietary cooling innovation.
Backed by 2 papers
A reasonably-timed market-intelligence product for the nascent UAM sector, but it competes directly with incumbent consultancies and rests on publicly available research rather than proprietary data.
Backed by 2 papers
A low-moat service business that lacks a proprietary technological edge and relies on a generic academic foundation.
A niche sourcing service with high operational risk and weak evidence, attempting to monetize a narrow academic research pipeline.
A simple, buildable triage tool that codifies expert orthodontic consensus, but it rests on a single consensus study (which itself admits major evidence gaps) and has a weak moat since the rules are public.
Backed by 2 papers
A mathematically sound improvement for high-precision robotics that lacks a specific commercial wedge and relies on a generic academic overview.
A focused environmental-screening service riding the rising regulatory wave around tire-derived pollutants like 6PPD-quinone, but built on a single regional study and facing the very consultancies it names as targets.
A technically plausible crash-evidence and alerting service whose biggest hurdle is access to intersection camera infrastructure and the regulatory/integration thicket of emergency and insurance partners, not the underlying CV.